ACR 20 rating is less of a weighted factor in trials where patients are also on methotrexate due to the proven effect methotrexate has on RA. The trial still showed an increase in the ACR20 rating with a higher dose of cpn10 showing that improvement increases with dosage. As the safety profile is 100% this would allow approval for the next trial to heftily increase the dose ranges and possibly trial a variant/ mutant of the original cpn10. Other key measurement targets were met with clinical significance and improvement in patient health and well being as a whole.
One must not forget even though the company has been around over 10 years this is still very new science( first in class). With the number of variations to the original compound and indications in which cpn10 may improve quality of patient life (without side effects) many more trials will need to be completed to optimise dosage and cpn10 variant to unlock the true potential.
Also beleive yesterdays result was a knee jerk reaction from nervous players.
CBZ Price at posting:
28.2¢ Sentiment: Buy Disclosure: Held
